Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity
It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, l...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2020, Vol.2020 (2020), p.1-8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2020 |
| creator | Liang, Shuang Wang, Dingding Zhang, Taie Jin, Zhi Kuang, Jiangying Xue, Jiang Zhang, Yuan Zhao, Fei Wu, Jing Jiang, Chunjie |
| description | It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P |
| doi_str_mv | 10.1155/2020/2308124 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7053482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A624689230</galeid><sourcerecordid>A624689230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-a12261cc11365fe4b623f17d2e4e2ea73ec845315619cda87f7c996b1b026b943</originalsourceid><addsrcrecordid>eNqN0c1rFDEYBvBBFFtqb54l4EWwY_MmmczkItSlH0JhQerBiyGTeaebOpOsyazL_vfNsutWPZlLAvnlScJTFK-BfgCoqnNGGT1nnDbAxLPimHEQpQQBzw9rzo-K05QeaB4NSKrky-KIMxCKNs1x8f2y79FOJPRk7rH8hiaS6xjW04LchDgGj-RugdEsNyR4MjOxc2HEybRhcJZ8cekHuTJ2CjER58mnsElk7fLheYvJTZtXxYveDAlP9_NJ8fXq8m52U97Orz_PLm5LK5SaSgOMSbAWgMuqR9FKxnuoO4YCGZqao21ExaGSoGxnmrqvrVKyhZYy2SrBT4qPu9zlqh2xs-inaAa9jG40caODcfrvHe8W-j780jWtuGhYDni3D4jh5wrTpEeXLA6D8RhWSTNeVxVlikGmb_-hD2EVff5eVlIxKqisn9S9GVA734d8r92G6gvJhGxUri2rs52yMaQUsT88GajeNqy3Det9w5m_-fObB_y7zwze78DC-c6s3X_GYTbYmycNnAmQ_BEkMbUe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2369204067</pqid></control><display><type>article</type><title>Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity</title><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Liang, Shuang ; Wang, Dingding ; Zhang, Taie ; Jin, Zhi ; Kuang, Jiangying ; Xue, Jiang ; Zhang, Yuan ; Zhao, Fei ; Wu, Jing ; Jiang, Chunjie</creator><contributor>Meinzen-Derr, Jareen K. ; Jareen K Meinzen-Derr</contributor><creatorcontrib>Liang, Shuang ; Wang, Dingding ; Zhang, Taie ; Jin, Zhi ; Kuang, Jiangying ; Xue, Jiang ; Zhang, Yuan ; Zhao, Fei ; Wu, Jing ; Jiang, Chunjie ; Meinzen-Derr, Jareen K. ; Jareen K Meinzen-Derr</creatorcontrib><description>It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2020/2308124</identifier><identifier>PMID: 32149088</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Abnormalities ; Alanine ; Alanine transaminase ; Anthropometry ; Body mass ; Body mass index ; Body size ; Cardiovascular diseases ; Children ; Children & youth ; Cholesterol ; Clinical Study ; Comorbidity ; Complications ; Dextrose ; Diabetes ; Endocrine therapy ; Glucose ; Growth factors ; Growth hormones ; Health aspects ; Health care ; Health risks ; Hepatitis ; Homeostasis ; Insulin ; Insulin resistance ; Insulin-like growth factors ; Laboratories ; Lipids ; Low density lipoprotein ; Markers ; Metabolism ; Obesity ; Obesity in children ; Risk analysis ; Risk factors ; Somatotropin ; Standard deviation ; Studies ; Therapy ; Thyroid gland ; Triglycerides ; Variance analysis ; Weight control</subject><ispartof>BioMed research international, 2020, Vol.2020 (2020), p.1-8</ispartof><rights>Copyright © 2020 Jing Wu et al.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 Jing Wu et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Jing Wu et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-a12261cc11365fe4b623f17d2e4e2ea73ec845315619cda87f7c996b1b026b943</citedby><cites>FETCH-LOGICAL-c499t-a12261cc11365fe4b623f17d2e4e2ea73ec845315619cda87f7c996b1b026b943</cites><orcidid>0000-0002-4612-8443 ; 0000-0001-9067-6829</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053482/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053482/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,4010,27904,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32149088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Meinzen-Derr, Jareen K.</contributor><contributor>Jareen K Meinzen-Derr</contributor><creatorcontrib>Liang, Shuang</creatorcontrib><creatorcontrib>Wang, Dingding</creatorcontrib><creatorcontrib>Zhang, Taie</creatorcontrib><creatorcontrib>Jin, Zhi</creatorcontrib><creatorcontrib>Kuang, Jiangying</creatorcontrib><creatorcontrib>Xue, Jiang</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><creatorcontrib>Zhao, Fei</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Jiang, Chunjie</creatorcontrib><title>Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.</description><subject>Abnormalities</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Anthropometry</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Cardiovascular diseases</subject><subject>Children</subject><subject>Children & youth</subject><subject>Cholesterol</subject><subject>Clinical Study</subject><subject>Comorbidity</subject><subject>Complications</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Endocrine therapy</subject><subject>Glucose</subject><subject>Growth factors</subject><subject>Growth hormones</subject><subject>Health aspects</subject><subject>Health care</subject><subject>Health risks</subject><subject>Hepatitis</subject><subject>Homeostasis</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Insulin-like growth factors</subject><subject>Laboratories</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Markers</subject><subject>Metabolism</subject><subject>Obesity</subject><subject>Obesity in children</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Somatotropin</subject><subject>Standard deviation</subject><subject>Studies</subject><subject>Therapy</subject><subject>Thyroid gland</subject><subject>Triglycerides</subject><subject>Variance analysis</subject><subject>Weight control</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0c1rFDEYBvBBFFtqb54l4EWwY_MmmczkItSlH0JhQerBiyGTeaebOpOsyazL_vfNsutWPZlLAvnlScJTFK-BfgCoqnNGGT1nnDbAxLPimHEQpQQBzw9rzo-K05QeaB4NSKrky-KIMxCKNs1x8f2y79FOJPRk7rH8hiaS6xjW04LchDgGj-RugdEsNyR4MjOxc2HEybRhcJZ8cekHuTJ2CjER58mnsElk7fLheYvJTZtXxYveDAlP9_NJ8fXq8m52U97Orz_PLm5LK5SaSgOMSbAWgMuqR9FKxnuoO4YCGZqao21ExaGSoGxnmrqvrVKyhZYy2SrBT4qPu9zlqh2xs-inaAa9jG40caODcfrvHe8W-j780jWtuGhYDni3D4jh5wrTpEeXLA6D8RhWSTNeVxVlikGmb_-hD2EVff5eVlIxKqisn9S9GVA734d8r92G6gvJhGxUri2rs52yMaQUsT88GajeNqy3Det9w5m_-fObB_y7zwze78DC-c6s3X_GYTbYmycNnAmQ_BEkMbUe</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Liang, Shuang</creator><creator>Wang, Dingding</creator><creator>Zhang, Taie</creator><creator>Jin, Zhi</creator><creator>Kuang, Jiangying</creator><creator>Xue, Jiang</creator><creator>Zhang, Yuan</creator><creator>Zhao, Fei</creator><creator>Wu, Jing</creator><creator>Jiang, Chunjie</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4612-8443</orcidid><orcidid>https://orcid.org/0000-0001-9067-6829</orcidid></search><sort><creationdate>2020</creationdate><title>Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity</title><author>Liang, Shuang ; Wang, Dingding ; Zhang, Taie ; Jin, Zhi ; Kuang, Jiangying ; Xue, Jiang ; Zhang, Yuan ; Zhao, Fei ; Wu, Jing ; Jiang, Chunjie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-a12261cc11365fe4b623f17d2e4e2ea73ec845315619cda87f7c996b1b026b943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abnormalities</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Anthropometry</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Cardiovascular diseases</topic><topic>Children</topic><topic>Children & youth</topic><topic>Cholesterol</topic><topic>Clinical Study</topic><topic>Comorbidity</topic><topic>Complications</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Endocrine therapy</topic><topic>Glucose</topic><topic>Growth factors</topic><topic>Growth hormones</topic><topic>Health aspects</topic><topic>Health care</topic><topic>Health risks</topic><topic>Hepatitis</topic><topic>Homeostasis</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Insulin-like growth factors</topic><topic>Laboratories</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Markers</topic><topic>Metabolism</topic><topic>Obesity</topic><topic>Obesity in children</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Somatotropin</topic><topic>Standard deviation</topic><topic>Studies</topic><topic>Therapy</topic><topic>Thyroid gland</topic><topic>Triglycerides</topic><topic>Variance analysis</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Shuang</creatorcontrib><creatorcontrib>Wang, Dingding</creatorcontrib><creatorcontrib>Zhang, Taie</creatorcontrib><creatorcontrib>Jin, Zhi</creatorcontrib><creatorcontrib>Kuang, Jiangying</creatorcontrib><creatorcontrib>Xue, Jiang</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><creatorcontrib>Zhao, Fei</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Jiang, Chunjie</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Shuang</au><au>Wang, Dingding</au><au>Zhang, Taie</au><au>Jin, Zhi</au><au>Kuang, Jiangying</au><au>Xue, Jiang</au><au>Zhang, Yuan</au><au>Zhao, Fei</au><au>Wu, Jing</au><au>Jiang, Chunjie</au><au>Meinzen-Derr, Jareen K.</au><au>Jareen K Meinzen-Derr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32149088</pmid><doi>10.1155/2020/2308124</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4612-8443</orcidid><orcidid>https://orcid.org/0000-0001-9067-6829</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2020, Vol.2020 (2020), p.1-8 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7053482 |
| source | PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Abnormalities Alanine Alanine transaminase Anthropometry Body mass Body mass index Body size Cardiovascular diseases Children Children & youth Cholesterol Clinical Study Comorbidity Complications Dextrose Diabetes Endocrine therapy Glucose Growth factors Growth hormones Health aspects Health care Health risks Hepatitis Homeostasis Insulin Insulin resistance Insulin-like growth factors Laboratories Lipids Low density lipoprotein Markers Metabolism Obesity Obesity in children Risk analysis Risk factors Somatotropin Standard deviation Studies Therapy Thyroid gland Triglycerides Variance analysis Weight control |
| title | Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A10%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20One-Year%20Growth%20Hormone%20Therapy%20on%20Cardiometabolic%20Risk%20Factors%20in%20Boys%20with%20Obesity&rft.jtitle=BioMed%20research%20international&rft.au=Liang,%20Shuang&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2020/2308124&rft_dat=%3Cgale_pubme%3EA624689230%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2369204067&rft_id=info:pmid/32149088&rft_galeid=A624689230&rfr_iscdi=true |